Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
Concert Pharmaceuticals, Inc. today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation
Poster Presentation
Title: CTP-543, A JAK1/JAK2 Inhibitor, Achieves Primary Endpoint in Interim Analysis of Phase 2 Trial in Alopecia Areata
Date and Time: Thursday, April 25, 2019 at 11:00 a.m. GMT
Poster Number: P6
Location: Exhibition Area
Lecture Series
Title: JAK Inhibitor CTP-543: Interim Results from a Phase 2 Trial in Alopecia Areata
Date and Time: Thursday, April 25, 2019, 4:15 – 4:45 p.m. GMT
Session: Sponsored Lecture
Room: Auditori
About CTP-543
CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders.
Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.
About Alopecia Areata
Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.
Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40. It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.
Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.
The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
Previous Posts
- Hair Loss Men and Women
- Expert Reveals Best-Kept Secret in the Fight Against Hair Loss on Good Morning America
- ReGrow to Launch Affordable Hair Regrowth Treatment
- Capillus Laser Cap for Hair Loss
- Global Anti-dandruff Agent Ingredients Market
- Preclinical Study of Hair Loss Therapeutic Candidate
- Male Androgenetic Alopecia
- Elite Solutions Hair Loss Specialists of Sacramento to Host Womens Hair Loss Seminar
